Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat
- PMID: 9231345
- DOI: 10.1111/j.2042-7158.1997.tb06795.x
Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat
Abstract
Because few pharmacokinetic studies of antibodies and their fragments have compared the influence of species origin and antibody size, the plasma pharmacokinetics of a single intravenous dose (0.7 mg kg-1) of 125I-labelled mouse, rat and human immunoglobulin G (IgG), and mouse F(ab')2 and Fab were investigated in the rat. IgG reached equilibrium after six distribution half-lives, i.e. only 36-50 h post-dosing, and the distribution volume was about four times the rat plasma volume. IgG elimination half-lives ranged from 5.33 to 8.10 days. Fragmentation of IgG into smaller fragments, F(ab')2 and Fab, resulted in pharmacokinetics that were molecular-weight-dependent with volume of distribution and systemic clearance values inversely related to antibody size. We conclude that antibody variability in terms of species origin and size influences antibody pharmacokinetics and should be carefully studied before selection of the best antibody for a clinical application.
Similar articles
-
Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin.Toxicon. 1998 Jan;36(1):93-114. doi: 10.1016/s0041-0101(97)00062-7. Toxicon. 1998. PMID: 9604285
-
Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies.J Immunol. 1987 Nov 1;139(9):3041-9. J Immunol. 1987. PMID: 3499463
-
Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use.Toxicon. 1998 Nov;36(11):1523-8. doi: 10.1016/s0041-0101(98)00144-5. Toxicon. 1998. PMID: 9792168
-
Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.Clin Pharmacokinet. 2003;42(8):721-41. doi: 10.2165/00003088-200342080-00002. Clin Pharmacokinet. 2003. PMID: 12846594 Review.
-
Stimulation of complement amplification by F(ab')(2)-containing immune complexes and naturally occurring anti-hinge antibodies, possible role in systemic inflammation.Autoimmun Rev. 2008 Jun;7(6):508-13. doi: 10.1016/j.autrev.2008.04.017. Epub 2008 May 12. Autoimmun Rev. 2008. PMID: 18558371 Review.
Cited by
-
Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.Adv Pharmacol. 2014;69:107-27. doi: 10.1016/B978-0-12-420118-7.00003-2. Adv Pharmacol. 2014. PMID: 24484976 Free PMC article. Review.
-
Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model.Macromol Biosci. 2020 May;20(5):e1900445. doi: 10.1002/mabi.201900445. Epub 2020 Mar 20. Macromol Biosci. 2020. PMID: 32196951 Free PMC article.
-
Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics.Breast Cancer (Dove Med Press). 2021 Oct 14;13:575-593. doi: 10.2147/BCTT.S331844. eCollection 2021. Breast Cancer (Dove Med Press). 2021. PMID: 34703307 Free PMC article. Review.
-
Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments.Toxicon. 2013 Sep;72:29-34. doi: 10.1016/j.toxicon.2013.04.005. Epub 2013 Apr 17. Toxicon. 2013. PMID: 23603317 Free PMC article.
-
Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins.Pharm Res. 2006 Aug;23(8):1743-9. doi: 10.1007/s11095-006-9018-1. Pharm Res. 2006. PMID: 16850270
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
